
C Garrison Fathman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10766311/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 2003, 9, 1144-1150.	30.7	1,174
2	Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation. Journal of Experimental Medicine, 2002, 196, 389-399.	8.5	1,012
3	Exploiting a natural conformational switch to engineer an interleukin-2 †superkine'. Nature, 2012, 484, 529-533.	27.8	438
4	Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature, 1996, 379, 343-346.	27.8	382
5	Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood, 2005, 105, 2220-2226.	1.4	379
6	The Subpopulation of CD4+CD25+ Splenocytes That Delays Adoptive Transfer of Diabetes Expresses L-Selectin and High Levels of CCR7. Journal of Immunology, 2002, 169, 2461-2465.	0.8	332
7	Essential Role of the E3 Ubiquitin Ligase Cbl-b in T Cell Anergy Induction. Immunity, 2004, 21, 167-177.	14.3	308
8	GRAIL. Immunity, 2003, 18, 535-547.	14.3	272
9	Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature, 1993, 365, 642-644.	27.8	265
10	Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 1997, 185, 1711-1714.	8.5	250
11	CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. Journal of Allergy and Clinical Immunology, 2002, 110, 460-468.	2.9	202
12	Adoptive Immunotherapy of Experimental Autoimmune Encephalomyelitis Via T Cell Delivery of the IL-12 p40 Subunit. Journal of Immunology, 2001, 167, 2379-2387.	0.8	185
13	Autoimmune diseases: genes, bugs and failed regulation. Nature Immunology, 2001, 2, 759-761.	14.5	174
14	Antigen-specific T cell–mediated gene therapy in collagen-induced arthritis. Journal of Clinical Investigation, 2001, 107, 1293-1301.	8.2	171
15	Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nature Immunology, 2004, 5, 45-54.	14.5	160
16	Molecular mechanisms of CD4+ T-cell anergy. Nature Reviews Immunology, 2007, 7, 599-609.	22.7	160
17	CD4+CD25+ T Cells Facilitate the Induction of T Cell Anergy. Journal of Immunology, 2001, 167, 4271-4275.	0.8	121
18	CD4+CD25+Regulatory T Cells and Their Therapeutic Potential. Annual Review of Medicine, 2006, 57, 381-402.	12.2	115

#	Article	IF	CITATIONS
19	Targeting Rare Populations of Murine Antigen-Specific T Lymphocytes by Retroviral Transduction for Potential Application in Gene Therapy for Autoimmune Disease. Journal of Immunology, 2000, 164, 3581-3590.	0.8	105
20	Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease. Journal of Immunology, 2007, 179, 6547-6554.	0.8	100
21	Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLoS ONE, 2015, 10, e0133627.	2.5	90
22	An array of possibilities for the study of autoimmunity. Nature, 2005, 435, 605-611.	27.8	89
23	Therapeutic Effects of Systemic Administration of Chaperone αB-Crystallin Associated with Binding Proinflammatory Plasma Proteins. Journal of Biological Chemistry, 2012, 287, 9708-9721.	3.4	79
24	L-selectin and β7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood, 2005, 106, 4009-4015.	1.4	73
25	Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nature Chemical Biology, 2012, 8, 990-998.	8.0	73
26	A Novel E3 Ubiquitin Ligase Substrate Screen Identifies Rho Guanine Dissociation Inhibitor as a Substrate of Gene Related to Anergy in Lymphocytes. Journal of Immunology, 2006, 177, 7559-7566.	0.8	69
27	Murine CD4+CD25+ Regulatory T Cells Fail to Undergo Chromatin Remodeling Across the Proximal Promoter Region of the IL-2 Gene. Journal of Immunology, 2004, 173, 4994-5001.	0.8	66
28	GRAIL Is Up-regulated in CD4+ CD25+ T Regulatory Cells and Is Sufficient for Conversion of T Cells to a Regulatory Phenotype. Journal of Biological Chemistry, 2007, 282, 9696-9702.	3.4	65
29	The Single Subunit Transmembrane E3 Ligase Gene Related to Anergy in Lymphocytes (GRAIL) Captures and Then Ubiquitinates Transmembrane Proteins across the Cell Membrane. Journal of Biological Chemistry, 2008, 283, 28497-28505.	3.4	63
30	Distinct B Cell Subpopulations Differ in Their Genetic Requirements for Activation by T Helper Cells. Immunological Reviews, 1982, 64, 137-160.	6.0	60
31	Cutting Edge: The Transmembrane E3 Ligase GRAIL Ubiquitinates the Costimulatory Molecule CD40 Ligand during the Induction of T Cell Anergy. Journal of Immunology, 2008, 181, 1622-1626.	0.8	54
32	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. Arthritis Research and Therapy, 2015, 17, 127.	3.5	53
33	T Cell Receptor (TCR) Engagement Leads to Activation-induced Splicing of  Tumor Necrosis Factor (TNF) Nuclear Pre-mRNA. Journal of Experimental Medicine, 1998, 188, 247-254.	8.5	52
34	Treatment of Autoimmune Disease by Adoptive Cellular Gene Therapy. Annals of the New York Academy of Sciences, 2003, 998, 512-519.	3.8	51
35	Retroviral Gene Therapy of Collagen-Induced Arthritis by Local Delivery of IL-4. Clinical Immunology, 2002, 105, 304-314.	3.2	45
36	GRAIL: a unique mediator of CD4 T″ymphocyte unresponsiveness. FEBS Journal, 2011, 278, 47-58.	4.7	45

#	Article	IF	CITATIONS
37	The Transmembrane E3 Ligase GRAIL Ubiquitinates and Degrades CD83 on CD4 T Cells. Journal of Immunology, 2009, 183, 438-444.	0.8	38
38	Naive CD4 T Cell Proliferation Is Controlled by Mammalian Target of Rapamycin Regulation of GRAIL Expression. Journal of Immunology, 2009, 182, 5919-5928.	0.8	36
39	Expression-Based Genome-Wide Association Study Links Vitamin D–Binding Protein With Autoantigenicity in Type 1 Diabetes. Diabetes, 2016, 65, 1341-1349.	0.6	33
40	Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7081-7086.	7.1	32
41	Adoptive cellular gene therapy of autoimmune disease. Autoimmunity Reviews, 2002, 1, 213-219.	5.8	24
42	Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15016-15023.	7.1	24
43	The Potential for Gene Therapy in the Treatment of Autoimmune Disease. Clinical Immunology, 2002, 104, 204-216.	3.2	22
44	DRB1*LY10 — a newDRB1 allele and its haplotypic association. Immunogenetics, 1990, 32, 214-217.	2.4	21
45	Inflammation and Hyperglycemia MediateDeaf1Splicing in the Pancreatic Lymph Nodes via Distinct Pathways During Type 1 Diabetes. Diabetes, 2015, 64, 604-617.	0.6	21
46	Rapid and Efficient Vascular Transport of Arginine Polymers Inhibits Myointimal Hyperplasia. Circulation, 2000, 102, 2629-2635.	1.6	20
47	Targeted gene therapy: frontiers in the development of ?smart drugs?. Trends in Biotechnology, 2004, 22, 304-310.	9.3	19
48	Gene Expression Analysis of the Pre-Diabetic Pancreas to Identify Pathogenic Mechanisms and Biomarkers of Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 609271.	3.5	18
49	Poly-l-Arginine Topical Lotion Tested in a Mouse Model for Frostbite Injury. Wilderness and Environmental Medicine, 2014, 25, 160-165.	0.9	15
50	Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. Journal of Experimental Medicine, 2014, 211, 1847-1856.	8.5	14
51	Clonotypic Antibodies which Stimulate T Cell Clone Proliferation. Immunological Reviews, 1984, 81, 21-38.	6.0	12
52	Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease?. Nature Clinical Practice Rheumatology, 2006, 2, 491-499.	3.2	11
53	Selective expansion of human regulatory T cells in nasal polyps, and not adjacent tissue microenvironments, in individual patients exposed to steroids. Clinical Immunology, 2017, 179, 66-76.	3.2	10
54	Impact of blood collection and processing on peripheral blood gene expression profiling in type 1 diabetes. BMC Genomics, 2017, 18, 636.	2.8	9

C GARRISON FATHMAN

#	Article	IF	CITATIONS
55	A gene therapy approach to treatment of autoimmune disease. Immunologic Research, 1998, 18, 15-26.	2.9	5
56	T-Cell Anergy: From Phenotype to Genotype and Back. Immunologic Research, 2003, 28, 255-264.	2.9	5
57	T Cell Anergy: Where It's LAT. Immunity, 2006, 24, 501-503.	14.3	5
58	Th1 unresponsiveness can be infectious for unrelated antigens. Immunology and Cell Biology, 1998, 76, 173-178.	2.3	4
59	Immunomodulatory vaccination in autoimmune disease. Endocrinology and Metabolism Clinics of North America, 2002, 31, 441-456.	3.2	4
60	CD4-positive/heat-stable antigen-positive thymocytes cause graft-versus-host disease across non-major histocompatibility complex incompatibilities. European Journal of Immunology, 1994, 24, 1706-1709.	2.9	3
61	Peptides as therapy of autoimmune disease. Diabetes/metabolism Reviews, 1993, 9, 239-244.	0.3	2
62	Stimulating the lymphocytes. Current Biology, 1993, 3, 558-559.	3.9	1
63	Allosensitized Memory CD4 T Cells Induce Chronic Graft Versus Host Disease Blood, 2006, 108, 449-449.	1.4	1
64	Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment Blood, 2005, 106, 696-696.	1.4	1
65	GRAIL, an E3 ubiquitin ligase, is necessary for anergy induction in CD4+ T cells. Autoimmunity Reviews, 2004, 3, 571-572.	5.8	0
66	Gene therapy for multiple sclerosis. , 2000, , 119-131.		0
67	CD4+CD25+ Regulatory T Cells as Adoptive Cell Therapy for Autoimmune Disease and for the Treatment of Graft-Versus-Host Disease. , 2008, , 231-252.		0